SecBot SecBot
PRESS-RELEASE ·Filed Jul 30, 2026

REGN

Regeneron Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The massive EPS beat and raised gross margin guidance, combined with the Sanofi Development Balance repayment that will structurally increase collaboration profits from Q3, create a strong positive catalyst. Monitor the Q3 2026 report for the first full quarter of post-repayment collaboration revenue and any updates on the cemdisiran PDUFA date in November 2026.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

REGN drug pipeline →

Otarmeni

● Neutral Named in this press release
Impact
Phase
Approved (accelerated approval)
Time to market
Already FDA-approved (April 23, 2026); commercially available in the U.S.
Next catalyst
BLA filing · 2026

What to watchOtarmeni's approval binary has passed and the drug is provided free in the U.S. under a government pricing deal, so it generates zero direct revenue. For Regeneron investors, EMA approval (under accelerated assessment review) is a modest upside tailwind but immaterial given the ultra-rare indication and free-access model. The stock's bigger catalysts are Eylea HD dosing expansions, the garetosmab PDUFA (August 2026), and Dupixent pipeline growth, not this drug.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$738.34
T+0 close · Jul 30, 2026 · via day close
Latest settled
+9.03%
T+60 · $805.02
Vs SPY
+6.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $738.34entry
  2. T+1 · 4mo ago +3.29%α +2.58% · $762.63
  3. T+5 · 3mo ago +4.57%α +0.95% · $772.11
  4. T+20 · 3mo ago +9.40%α +5.43% · $807.71
  5. T+60 · 25d ago +9.03%α +6.57% · $805.02
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Regeneron reported Q2 2026 non-GAAP EPS of $14.29, a 40.1% beat vs consensus of $10.20, on total revenue of $4.29B (+17% YoY), driven by strong Dupixent (+38%), EYLEA HD (+52%), and Libtayo (+30%) sales. The Sanofi Development Balance was fully repaid, which will boost collaboration profits starting Q3, and the company raised its full-year guidance on gross margins and narrowed R&D and SG&A ranges. The massive EPS beat and raised fundamentals support a bullish read, though GAAP net income declined 7% due to a $127M IPR&D charge and higher tax rate.

Key Financial Metrics

EPS
$14.29
est $10.20 · +40.1%
Revenue
$4.3B
est $3.8B · +12.0% · +17.0% YoY
Rating
strong beat
Free Cash Flow
$1.4B
Gross Margin
78%

Key Facts

  • Q2 2026 total revenue $4.29B (+17% YoY), above $3.83B consensus
  • Non-GAAP EPS $14.29 vs consensus $10.20 (+40.1% beat)
  • GAAP EPS $12.23 (includes $1.02 negative IPR&D impact)
  • Dupixent global net sales +38% to $6.0B; EYLEA HD U.S. +52% to $596M; Libtayo global +30% to $489M
  • Sanofi Development Balance fully repaid as of Q2 end, boosting collaboration profits from Q3
  • Full-year 2026 guidance: GAAP gross margin raised to 78-79% (from 77-78%); non-GAAP R&D narrowed to $5.95-6.05B; GAAP SG&A narrowed to $2.83-2.96B
  • Share repurchases of $1.2B in Q2, $2.0B in H1 2026; $2.5B remaining under buyback programs
  • Cemdisiran NDA accepted under FDA priority review for gMG with target action date Nov 2026

Financial Impact

Non-GAAP EPS beat consensus by 40.1% ($14.29 vs $10.20); revenue beat by $460M (12% above $3.83B consensus)

revenueepsgross margincollaboration revenueshare repurchases

Risk Factors

  • GAAP net income declined 7% YoY due to $127M IPR&D charge and higher tax rate (15.1% vs 8.4%)
  • EYLEA franchise U.S. sales declined 12% YoY as EYLEA HD partially cannibalizes EYLEA
  • Fianlimab Phase 3 melanoma trial missed primary endpoint (PFS vs pembrolizumab)
  • Temporary manufacturing interruption at Limerick facility impacted Q2 gross margins (GAAP 78% vs 83% YoY)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3335868

Track record

53 reports on REGN

Performance horizon

10 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 16 of 20 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (10h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026